Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
===================================================================================================

* Tamer Basel Shabaneh
* Andrew R Stevens
* Sylvia M Stull
* Kristen R Shimp
* Brandon W Seaton
* Ekram A Gad
* Carla A Jaeger-Ruckstuhl
* Sylvain Simon
* Amanda L Koehne
* Jason P Price
* James M Olson
* Benjamin G Hoffstrom
* David Jellyman
* Stanley R Riddell